Profil
Daniel Harris Rosenbaum is currently the Chief Executive Officer at Kaydence Pharma USA. Prior to this, he was the Chief Executive Officer at NattoPharma ASA from 2015 to 2018.
He also worked as the General Manager-Nutraceuticals & Pharmaceutical at FMC Corp.
Mr. Rosenbaum completed his undergraduate degree at Cornell University and earned an MBA from Tuck School of Business at Dartmouth.
Postes actifs de Dan Rosenbaum
| Sociétés | Poste | Début |
|---|---|---|
Kaydence Pharma USA
Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases | Directeur Général | - |
Anciens postes connus de Dan Rosenbaum
| Sociétés | Poste | Fin |
|---|---|---|
| NATTOPHARMA ASA | Directeur Général | 10/02/2018 |
| FMC CORPORATION | Corporate Officer/Principal | - |
Formation de Dan Rosenbaum
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
FMC Corp.
FMC Corp. Chemicals: AgriculturalProcess Industries Operates as an agricultural sciences company which produces insecticides, herbicides and fungicides & crop nutrition and seed treatment products | Process Industries |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NattoPharma ASA
NattoPharma ASA Pharmaceuticals: MajorHealth Technology Manufactures, distributes, markets and sells vitamin K2 products | Health Technology |
Tuck School of Business at Dartmouth
Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kaydence Pharma USA
Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases | Health Technology |
















